BACKGROUND: Antithymocyte globulin (ATG) is an important component of conditioning regimens to prevent severe graft-versushost disease (GVHD) in patients undergoing unmanipulated, haploidentical stem cell transplantation (haplo-SCT). However, to the authors' knowledge, the optimal dose of ATG is unknown. METHODS: In this prospective, randomized trial, the authors compared the long-term outcomes of 2 ATG doses (rabbit thymoglobulin) used in myeloablative conditioning before unmanipulated haplo-HSCT. Patients were randomly assigned (1:1) to received 10 mg/kg (ATG-10) or 6 mg/kg (ATG-6) of ATG. Analysis of disease-free survival, GVHD-free/recurrence-free survival (GRFS), disease recurrence, nonrecurrence mortality, and chronic GVHD (cGVHD) included the entire population. Late effects were assessed in disease-free patients who had survived for at least 6 months and had received regular follow-up evaluations. RESULTS: A total of 224 patients were recruited. The median follow-up period was 1614 days (range, 28-1929 days). The rate of infection-related deaths in ATG-10 arm was double that of the ATG-6 arm (14.3% vs 7.1%; P 5.084). The 5-year cumulative incidence was comparable between the ATG-6 and ATG-10 groups for disease recurrence (12.8% vs 13.4%; P 5.832) and nonrecurrence mortality (11.6% vs 17.0%; P 5.263). The 5-year probability of disease-free survival was comparable between the groups (75.6% vs 69.6%; P 5.283). The 5-year cumulative incidence of cGVHD was found to be higher with ATG-6 (75.0% vs 56.3% [P 5.007] and moderate-to-severe cGVHD: 56.3% vs 30.4% [P<.0001]) as well as that for late effects (71.2% vs 56.9%; P 5.043). The 5-year probability of GRFS was higher in the ATG-10 group (41.0% vs 26.8%; P 5.008). In the multivariate analysis, ATG-10 was found to be associated with a lower risk of cGVHD and improved GRFS. CONCLUSIONS: ATG-10 was found to be associated with better GVHD prevention and superior GRFS, but an increase in infection-related deaths. Cancer 2017;123:2881-92.
INTRODUCTION
For patients who require hematopoietic stem cell transplantation (HSCT) and who do not have a matched donor, a human leukocyte antigen (HLA)-haploidentical related donor is one of the most important alternative sources of stem cells. In recent years, considerable progress has been made in unmanipulated haploidentical HSCT (haplo-HSCT). For example, antithymocyte globulin (ATG) has been used in conditioning regimens to prevent severe graft-versus-host disease (GVHD), as demonstrated by the encouraging results of our previous study. 1 However, although several studies have suggested suitable doses of ATG in matched unrelated donor transplantations, 2, 3 to our knowledge to date, the optimal dose of ATG with respect to the prevention of severe GVHD after unmanipulated haplo-HSCT is unknown.
Therefore, an open-label, prospective, randomized trial was designed to compare the clinical outcomes of 10 mg/kg of ATG (ATG-10) and 6 mg/kg of ATG (ATG-6) as part of the conditioning regimens for unmanipulated haplo-HSCT recipients. 4 The study demonstrated that the risk of acute GVHD (aGVHD) was higher in the ATG-6 group than in the ATG-10 group. The incidence and severity of toxicity and infection, with the exception of Epstein-Barr virus reactivation, were comparable between the 2 treatment arms. The 1-year probability of disease recurrence, nonrecurrence mortality (NRM), and survival also were comparable between the groups. The relatively short observation period made evaluating long-term clinical outcomes difficult, and the long-term influence of the 2 doses of ATG after haplo-HSCT remained unknown. In addition, because the long-term survival rate after HSCT often is good, the long-term health status of these patients is an important parameter to monitor, and late effects have become the principal threat to the long-term health of survivors. However, to our knowledge, there have been no studies to date regarding the influence of different doses of ATG on late effects after haplo-HSCT.
Herein, we present the results of the extension study demonstrating the influence of 2 doses of ATG on longterm clinical outcomes in unmanipulated haplo-HSCT recipients.
MATERIALS AND METHODS

Study Design
An open-label, prospective, randomized trial was conducted at Peking University People's Hospital Institute of Hematology (PUIH) in Beijing, China, to compare 2 doses of ATG (rabbit thymoglobulin) (6 mg/kg vs 10 mg/ kg) in patients receiving myeloablative conditioning before undergoing unmanipulated haplo-HSCT; the full details of the study design have been published elsewhere. 4 The study protocol was approved by the ethics committee of the Peking University People's Hospital.
Patients
Patients aged 15 to 60 years with a diagnosis of de novo acute myeloid leukemia or acute lymphoblastic leukemia in first or second complete remission (CR), chronic myeloid leukemia in first or second chronic phase, or myelodysplastic syndrome with <20% blasts were eligible for inclusion. Patients were recruited between December 2010 and May 2012. The final study endpoint was March 31, 2016. Written informed consent was obtained from all of the patients/guardians.
Randomization and Adjudication of GVHD Diagnosis
The donor-recipient pairs were randomly assigned in a 1:1 ratio to either the group receiving the 6-mg/kg dose of ATG (ATG-6) or the group receiving the 10-mg/kg dose of ATG (ATG-10) by the subinvestigator (the treating physician in our transplant center) according to a computer-generated randomization system. Case report forms included detailed, structured data regarding organ involvement, which were verified by medical record inspection. On the basis of these data, a blinded, independent review panel of experts determined whether a patient had GVHD and, when present, the grade. Discordances were adjudicated by majority rule.
Procedures
Full details of the study procedures have been reported previously. 4 Briefly, patients were conditioned using 1 of 2 regimens. Regimen 1, an intensive chemotherapy-based regimen, consisted of the following: cytarabine at a dose of 4 g/m 2 /day from days -10 to -9, busulfan at a dose of 3.2 mg/kg/day administered intravenously on days -8 to -6, cyclophosphamide at a dose of 1.8 g/m 2 /day from days -5 to -4, and semustine at a dose of 250 mg/m 2 on day -3. Patients with T-cell acute lymphoblastic leukemia or incompletely eradicated tumor masses were conditioned with a total body irradiation (TBI)-based regimen (regimen 2). Regimen 2 consisted of TBI (770 centigrays in a single fraction) with particle shielding of the lungs on day -6, and treatment from days -5 to -3 was the same as for patients receiving regimen 1.
ATG (thymoglobulin [rabbit ATG]; Imtix SangStat, Lyon, France) was administered from days -5 to -2. Patients in the ATG-10 group received 2.5 mg/kg/day, and patients in the ATG-6 group received 1.5 mg/kg/day. Patients received scheduled dexamethasone at a dose of 5 mg/day as part of the administration of ATG.
Outcomes
Comorbidities were assessed based on the hematopoietic cell transplantation-specific comorbidity index (HCT-CI). 5 Disease risk at the time of diagnosis was reported according to the criteria of Armand et al. 6 In this study, aGVHD was diagnosed according to the Glucksberg criteria, 7 and chronic GVHD (cGVHD) was diagnosed according to the National Institutes of Health criteria for global cGVHD scoring (mild, moderate, or severe). 8 Diagnoses were mainly based on clinical manifestations. The maximum grade and severity were reported for aGVHD/ cGVHD. To determine the severity of the conditions, scoring was based on the Common Terminology Criteria for Adverse Events (version 3.0). 9 This system grades conditions as mild (grade 1), moderate (grade 2), severe (grade 3), life-threatening or disabling (grade 4), or fatal (grade 5). The protocols for the diagnosis and prevention of late effects have been described in detail previously.
The primary endpoints were the occurrence of grades 3 to 4 aGVHD, which have been reported previously in detail. 4 The following outcomes were examined in this extension study: cGVHD, disease recurrence, NRM, disease-free survival (DFS), GVHD-free/recurrence-free survival (GRFS), and late effects. DFS was defined as the time between transplantation and either leukemia recurrence or death (ie, treatment failure as defined by DFS). GRFS was defined as the time between transplantation and the development of GVHD (grade 3 to 4 aGVHD or cGVHD requiring systemic immunosuppressive treatment), disease recurrence, or death (ie, treatment failure as defined by GRFS). 11 Disease recurrence was defined by morphologic evidence of disease in the peripheral blood, bone marrow, or extramedullary sites, or by the recurrence and sustained presence of pretransplantation chromosomal abnormalities. Patients who demonstrated minimal residual disease were classified as having developed disease recurrence. NRM was defined as death after HSCT without disease progression or recurrence. Time to cGVHD was calculated as the time from transplantation to the onset of cGVHD. Time to late effects was calculated as the time from transplantation to the onset of late effects.
All outcomes were assessed at the time of last contact. The entire population was included in the analysis of DFS, GRFS, disease recurrence, NRM, and cGVHD. Late effects were assessed in disease-free patients who had survived 6 months and had received regular follow-up evaluations since their HSCT; patients who died (7 in the ATG-6 group and 9 in the ATG-10 group), developed disease recurrence (3 in the ATG-6 group and 3 in the ATG-10 group), or received donor lymphocyte infusion (DLI) (5 in the ATG-6 group and 5 in the ATG-10 group) within 6 months of HSCT were excluded.
Statistical Analysis
Continuous variables were compared using the MannWhitney U test; categorical variables were compared using the chi-square and Fisher exact tests. Survival probabilities were estimated using the Kaplan-Meier method. The prevalence of late effects was determined and 3 outcomes were assessed: any late effects (grade 1-5), severe or lifethreatening or fatal late effects (grade 3-5), and multiple late effects (2) . For patients with > 1 late effect, the highest grade was used in the analysis. Competing risk analyses were used to calculate the cumulative incidence of cGVHD, late effects, disease recurrence, and NRM using the Gray test to examine between-group differences. 12 Potential prognostic factors for 5-year clinical outcomes after transplantation were evaluated by multivariate analysis using Cox proportional hazards regression with a backward-stepwise model selection approach. Factors included in the regression model for disease recurrence, NRM, DFS, and late effects were underlying diseases (acute leukemia vs others), disease risk at time of diagnosis (high, intermediate, or low risk), HCT-CI score (0, 1-2, or 3), HLA disparity (2-3 vs 1), donor-recipient sexmatched (female-male vs others), donor-recipient relation (mother-child vs others), conditioning regimens (TBI vs chemotherapy), ATG dose (6 mg/kg vs 10 mg/kg), aGVHD (negative to grade 1 vs grade 2-4), and cGVHD (negative, mild, moderate, or severe). The abovementioned factors, with the exception of cGVHD, were included in the regression model for GRFS and cGVHD. Independent variables demonstrating a P value > .1 were sequentially excluded from the model, and the level of significance was set at P < .05. All of the reported P values were based on 2-sided hypothesis tests. The final model for each outcome is reported. Data analyses were primarily conducted using SPSS statistical software (IBM Corporation, Armonk, NY), and R statistical software (version 2.6.1; http://www.r-project.org) was used for the competing risk analysis.
The study was registered at www.chictr.orgas (no. ChiCTR-TRC-11001761).
RESULTS
The patient population has been described in detail elsewhere. 4 A total of 224 patients (112 each in the ATG-6 and ATG-10 groups) with a median age of 28 years (range, 14-58 years) underwent unmanipulated haplo-HSCT between December 2010 and May 2012 at the PUIH. The median follow-up after HSCT was 1614 days (range, 28-1929 days) for all patients and 1681 days (range, 1425-1929 days) for only surviving cases. The patient, disease, and transplantation characteristics are summarized in Table 1 .
At the time of last follow-up, 14 patients in the ATG-6 group and 15 patients in the ATG-10 group had experienced disease recurrence. The 5-year cumulative incidence of disease recurrence (including minimal residual disease occurrence) was comparable between the ATG-6 and ATG-10 groups (14.3% [95% confidence interval (95% CI), 7.8%-20.8%] in the ATG-6 group and 17.0% [95% CI, 10.0%-24.0%] in the ATG-10 group; P 5 .568) (Fig. 1A) . Of these patients, 20 patients received DLI plus chemotherapy, 1 patient received chemotherapy alone, 1 patient received chemotherapy plus radiotherapy, 1 patient underwent a second allogeneic HSCT, and 6 patients received no further therapy. Thirteen patients achieved CR after further therapy (DLI plus chemotherapy in 11 patients, chemotherapy plus radiotherapy in 1 patient, and second allogeneic HSCT in 1 patient). Of these, 7 patients did not develop disease recurrence again (5 patients were still alive at a median follow-up of 1151 days [range: 119-1346 days] after disease recurrence and 2 patients died after infection), and 6 patients developed disease recurrence again; of these patients, 3 died of disease recurrence within a median 71 days (range, 67-248 days) after first disease recurrence. Among the 29 patients with disease recurrence, 16 failed to achieve remission and 15 died of disease recurrence within a median 61 days (range, 6-379 days) after disease recurrence. Multivariate analysis failed to demonstrate significant differences in recurrence rates between the ATG doses, but moderate cGVHD was found to be associated with a significantly decreased risk of disease recurrence compared with no cGVHD ( Table 2 ). The late-onset infection and causes of NRM are described in Table 3 and Table 4 , respectively. The infection-related deaths in the ATG-10 arm were (Fig. 1B) . Multivariate analysis failed to demonstrate a significant difference in NRM between the ATG doses. HCT-CI scores of 1 to 2 and 3 both significantly increased NRM risk compared with an HCT-CI score of 0. Female donor-male recipient combinations also correlated with NRM after haplo-HSCT (Table 2) .
A total of 147 patients experienced cGVHD after HSCT (84 in the ATG-6 group and 63 in the ATG-10 group). The median time from transplantation to the occurrence of cGVHD was 183 days (range, 92-1157 days) in the ATG-6 group and 177 days (range, 106-590 days) in the ATG-10 group (P 5 .677). The 5-year cumulative incidence of cGVHD and moderate-to-severe cGVHD was found to be significantly higher in the ATG-6 group compared with the ATG-10 group Figs. 2A-2C ). Time spent receiving immunosuppressive therapy was 322 days (range, 28-1715 days) for the ATG-6 group, which was longer than that for the ATG-10 group (275 days [range, 61-1613 days]), although the difference was not statistically significant (P 5 .093). In the multivariate analysis, the higher ATG dose was found to be significantly Abbreviations: 95% CI, 95% confidence interval; aGVHD, acute graft-versushost disease; ATG, antithymocyte globulin; cGVHD, chronic graft-versus-host disease; DFS, disease-free survival; GRFS, graft-versus-host disease-free/recurrence-free survival; HCT-CI, hematopoietic cell transplantation-specific comorbidity index; HLA, human leukocyte antigen; HR, hazard ratio. Abbreviations: ATG-6, patients treated with 6 mg/kg of antithymocyte globulin; ATG-10, patients treated with 10 mg/kg of antithymocyte globulin; HSCT, hematopoietic stem cell transplantation.
associated with a lower risk of total cGVHD and moderate-to-severe cGVHD ( Table 2 ).
The 5-year probability of DFS in the ATG-6 and ATG-10 groups was 75.6% (95% CI, 67.5%-83.7%) and 69.6% (95% CI, 61.0%-78.2%), respectively (P 5 .283) (Fig. 3A) . The 5-year probability of GRFS was significantly higher in the ATG-10 group compared with the ATG- (Fig. 3C) . The multivariate analysis failed to demonstrate a significant difference between the ATG doses for DFS, but cGVHD and an HCT-CI score of 0 were found to be associated with a significantly improved DFS. The higher dose of ATG was associated with significantly improved GRFS compared with the lower dose of ATG (Table 2) .
Of the 192 patients who were disease free at 6 months, 123 (64.1%) experienced at least 1 late effect and 69 (35.9%) reported late effects of grades 3 to 5. Furthermore, 83 (43.2%) of the HSCT survivors experienced 2 late effects, and 55 patients (28.6%) experienced 3 late effects ( Table 5 ). The median time to the onset of the first late effect was 350 days (range, 60-1457 days) for ATG-6 recipients and 371 days (range, 88-1468 days) for ATG-10 recipients (P 5 .760). The 5-year cumulative incidence of any late effects (grades 1-5) was found to be significantly higher among ATG-6 recipients compared with ATG-10 recipients (71.2% [95% CI, 62.1%-80.3%] for ATG-6 and 56.9% [95% CI, 46.8%-67.0%] for ATG-10 [P 5 .043]) (Fig. 4A) . The 5-year cumulative incidence of late effects of grades 3 to 5 and multiple late effects also was comparable between the ATG-6 and ATG-10 groups (Fig. 4B-4D 024]) . However, the prevalence of late effects of grades 3 to 5 for patients with and without cGVHD was comparable (37.7% vs 31.7%; P 5 .611). In the multivariate analysis, an HCT-CI score of 3 and severe cGVHD were found to be the most important risk factors for late effects after haplo-HSCT (Table 2) .
DISCUSSION
In the current study, we present the long-term extension data from a randomized trial comparing the clinical outcomes of 2 different doses of rabbit ATG used as part of the conditioning regimen for patients undergoing unmanipulated haplo-HSCT. We observed that although the rates of NRM, disease recurrence, and DFS were comparable between the ATG-6 and ATG-10 groups, the incidence of cGVHD and any late effects was lower, and the probability of GRFS was significantly improved in the ATG-10 group compared with the ATG-6 group. These findings suggest the superiority of the dose of 10 mg/kg of ATG with better GVHD prevention in this patient population. To our knowledge, this is the first long-term extension study to investigate the optimal dose of ATG in unmanipulated haplo-HSCT recipients. The prospective and randomized design of the initial study laid the foundation for the reliability of these results. In addition, the much better overall outcome noted in the current study compared with the results from "Western" or Japanese centers could be related to the young patient age and no effects of the degree of HLA mismatch on survival in our haploidentical transplant protocol.
Several studies have demonstrated that the inclusion of ATG in conditioning regimens results in significantly lower rates of cGVHD after allogeneic transplantation. 13, 14 In a study of HLA-identical sibling donor HSCT, Mohty et al 15 observed that the incidence of cGVHD was significantly higher in patients receiving higher doses of ATG (7.5-100 mg/kg) compared with patients receiving a low dose (2.5 mg/kg). In contrast, Bacigalupo et al 16 observed that there was no significant difference in the incidence of extensive cGVHD according to ATG dose (38% for a dose of 7.5 mg/kg and 41% for a dose of 15 mg/kg) in unrelated donor transplantation. These inconsistent results may reflect the different donor types in these studies. In addition, the median follow-up times were 413 days and 530 to 1040 days in 
Abbreviations: ATG-6, patients treated with 6 mg/kg of antithymocyte globulin; ATG-10, patients treated with 10 mg/kg of antithymocyte globulin.
the studies by Mohty et al 15 and Bacigalupo et al 16 , respectively, which are relatively short follow-up periods and make the identification of the long-term protective effects of ATG against cGVHD difficult. Similarly, in our short-term trial, there was no difference noted with regard to the occurrence of moderate-to-severe cGVHD between the ATG-6 and ATG-10 groups. 4 However, over the long term, the incidence of cGVHD, particularly moderate-tosevere cGVHD, was found to be significantly higher in the ATG-6 group compared with the ATG-10 group. Chawla et al 17 reported that high serum levels of ATG immediately before graft infusion are associated with a low likelihood of cGVHD. Therefore, higher ATG doses may provide a more prolonged protective effect against cGVHD in unmanipulated haplo-HSCT recipients.cGVHD is associated with a strong antileukemic effect and a significantly reduced risk of disease recurrence after HSCT. 18, 19 Furthermore, several studies have failed to demonstrate a significant effect of ATG, or different doses of ATG, on the rate of disease recurrence. 15, 16, 20, 21 In the current study, although the ATG-10 group demonstrated a slightly increased rate of disease recurrence compared with the ATG-6 group, the difference was not statistically significant, and the multivariate analysis failed to indicate a significant difference in the recurrence rate between doses. These results suggest that the higher dose of ATG did not significantly decrease the graft-versusleukemia (GVL) effect compared with the lower dose. However, the majority of the patients included in the current study had acute leukemia in first or second CR, and the recurrence rate in these patients is relatively low. 1 Therefore, the results may not accurately reflect the influence of different doses of ATG on disease recurrence. In addition, although the dose of 10 mg/kg of ATG was found to decrease the relative incidence of cGVHD, which might have an adverse effect on NRM, 22 the NRM rate was comparable between the study groups. Some studies observed that even severe cGVHD was not associated with an increased risk of NRM. 19, 23 Yan et al 24 also observed that of 305 patients who died after unmanipulated haplo-HSCT, GVHD was cited as the cause of death in only 19 of them (6.2%). These outcomes may be partially attributable to the extensive experience of the physicians at PUIH (which to the best of our knowledge is the biggest HSCT center in China) in treating cGVHD, resulting in many patients with cGVHD avoiding NRM. Thus, the significantly lower incidence of cGVHD associated with the dose of 10 mg/kg of ATG resulted in a significantly higher rate of 5-year GRFS compared with the dose of 6 mg/kg. The significant benefit of ATG on the GRFS rate has been demonstrated previously. 25 Compared with patients in the ATG-6 arm, the rate of infection-related deaths among patients in the ATG-10 arm was approximately double. In addition, the patients in the ATG-10 arm experienced superior GRFS (Fig. 3B) , although it remains controversial to use GRSF as the ultimate endpoint defining superiority. These results suggest that further studies are needed to investigate the optimal dose of rabbit ATG.
Late effects have become the principal threat to the long-term health of patients after unmanipulated haplo-HSCT. Mo et al 26 observed that ATG could reduce the occurrence of chronic lung disease after HSCT. We also observed that the incidence of multiple late effects among haplo-HSCT recipients was lower than that of identical sibling donor HSCT recipients, 10 which may be due to the inclusion of ATG in the conditioning regimen of haplo-HSCT recipients. However, to the best of our knowledge, there have been no studies to date that have focused on the influence of different doses of ATG on the late effects of HSCT. In the current study, the cumulative incidence of any late effects (grades 1-5) was found to be significantly higher in the ATG-6 group compared with the ATG-10 group. This may be due to the significant reduction of cGVHD in the ATG-10 group, because cGVHD is considered to be the most important risk factor for late effects. 27 We also observed that the prevalence of any and multiple late effects was higher among recipients with cGVHD compared with those without, and moderate-to-severe cGVHD was a risk factor for multiple late effects in the multivariate analysis. However, the GVL effect is important to clear the leukemic cells after allogeneic HSCT, and GVHD may be inevitable. As noted above, cGVHD may decrease the risk of disease recurrence and improve the DFS rate; thus, the improvement in DFS after haplo-HSCT may be partially at the cost of impairment to long-term health status. However, the GRFS rate and the late effects burden in the ATG-10 group were both improved compared with the ATG-6 group; thus, the dose of 10 mg/kg of ATG may balance the benefits of the GVL effect against the toxicity of GVHD.
In addition to the ATG dose, the results of the current study identified other factors that significantly influenced the clinical outcomes. An HCT-CI score of 3 was found to significantly increase the risk of NRM, which was in accordance with previous reports. 28 Furthermore, patients who received a transplant from their mothers were found to have a higher risk of moderate-to-severe cGVHD and poorer GRFS. In a previous study, we observed that the frequency of aGVHD (grade 2) was higher in patients who received transplants from their mothers compared with those who received transplants from their fathers, 29 and aGVHD of grade 2 was significantly associated with a poorer GRFS in our multivariate analysis. However, the number of patients with an HCT-CI score of 1 or who received a transplant from their mothers was comparable between the ATG-6 and ATG-10 groups in the current study, and the superior outcomes of the ATG-10 group should not be explained by these variables.
Although the dose of 10 mg/kg of ATG demonstrated superiority to the dose of 6 mg/kg in haplo-HSCT recipients, this prospective, randomized study was only conducted in a single center. Given that many centers in China use our modality to treat patients who undergo haplo-HSCT, a prospective multicenter study is needed to confirm these results.
Patients receiving ATG at a dose of 10 mg/kg as part of the conditioning regimen for unmanipulated haplo-HSCT were found to have a lower risk of cGVHD and late effects, improved GRFS, and similar overall survival compared with patients receiving a dose of 6 mg/kg of ATG. Therefore, further clinical trials are needed to address which is the optimal dose of ATG for conditioning regimens for unmanipulated haplo-HSCT recipients.
